Wallach Beth Should Go Back to Studying Their Aleph, Bet
Upcoming FDA Advisory Committee Mtg. is not a binary event for the Company. I would expect the share price to go down, but only slightly with a negative vote. It has already retraced 10% since last week. IMHO, upside is also limited by 25% of current price. This is a low risk bet based on diverse revenue streams, including multiple royalty surprises. However, weak pipeline needs to be addressed. Based on CEO's M & A experience, if Serada fails, I wouldn't be surprised if they would sell the Company north of $8.